EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
L Y DirixJ Verweij

Abstract

In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, pancreatic and colorectal cancer. EO9 was given as a 5 min i.v. infusion at a weekly dose of 12 mg/m2. 92 patients were entered; 22 with breast cancer, 26 with colon cancer, 24 with pancreatic cancer and 20 with gastric cancer. In general, the drug was well tolerated with nausea and vomiting occurring in 26.42 and 13.3% of courses, respectively. Reversible proteinuria was the main toxicity occurring in 45% of courses. Antitumour activity was not observed. At this dose and schedule, EO9 is not an active drug in the type of tumour studied.

References

May 15, 1994·International Journal of Radiation Oncology, Biology, Physics·J A PlumbP Workman
Jun 15, 1994·Journal of the National Cancer Institute·J H SchellensJ Verweij
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H R HendriksJ A Double

❮ Previous
Next ❯

Citations

Oct 16, 2001·European Journal of Medicinal Chemistry·W A Denny
Sep 30, 2000·Bioorganic & Medicinal Chemistry Letters·L GarutiM Castelli
Aug 7, 2001·Anti-cancer Drugs·J H SchellensUNKNOWN EORTC Early Clinical Studies Group
May 8, 2007·Clinical Oncology : a Journal of the Royal College of Radiologists·S R McKeownK J Williams
Apr 19, 2012·British Journal of Pharmacology·Roger M PhillipsUNKNOWN EORTC-Pharmacology and Molecular Mechanism Group
Oct 23, 2004·Biochemical Pharmacology·Roger M PhillipsIan J Stratford
Sep 6, 2006·The Journal of Urology·Rajiv PuriRoger M Phillips
Jul 5, 2005·Expert Opinion on Investigational Drugs·R M Phillips
Dec 24, 2005·Expert Opinion on Biological Therapy·Girja S Shukla, David N Krag
Dec 23, 2011·Expert Opinion on Investigational Drugs·Vladimir Yutkin, Joseph Chin
May 10, 2002·The Journal of Pharmacy and Pharmacology·M A ElliottG W Halbert
Jul 5, 2003·Lancet·Joseph F Pizzolato, Leonard B Saltz
Nov 9, 2016·Cancer Investigation·Hamed Manoochehri KhoshinaniRezvan Najafi
Jun 24, 2017·Expert Opinion on Drug Metabolism & Toxicology·R M PhillipsG J Peters
Sep 20, 2017·Journal of the National Cancer Institute·Ahmed SalemCorinne Faivre-Finn
Jan 27, 2016·Cancer Chemotherapy and Pharmacology·Roger M Phillips
Jan 1, 2009·Drug Target Insights·Asher BegleiterFrank S Guziec
Nov 30, 2004·Cancer Investigation·William A Denny
May 28, 2021·World Journal of Gastrointestinal Oncology·Ross KingNoel E Donlon
May 2, 2018·Journal of Medicinal Chemistry·Kuojun ZhangSheng Jiang
Aug 17, 2021·Frontiers in Oncology·Yue LiXiao-Feng Li

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
H R HendriksJ A Double
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
N RobertsonI J Stratford
© 2021 Meta ULC. All rights reserved